Tempus AI (NasdaqGS:TEM) Q4 2025 Earnings call February 24, 2026 04:30 PM ET Company ParticipantsCasey Woodring - VP of Equity ResearchDan Brennan - Managing DirectorElizabeth Krutoholow - VP of Investor RelationsEric Lefkofsky - CEOJames William Rogers - CFOJesse Case - Managing DirectorMark Massaro - DirectorMark Schappel - Managing DirectorSubbu Nambi - Senior Managing DirectorConference Call ParticipantsAndrew Brackmann - Equity Research AnalystBradley Bowers - Director and Senior Research AnalystCallum ...

Tempus AI (NasdaqGS:TEM) Q4 2025 Earnings call February 24, 2026 04:30 PM ET Speaker12day, and thank you for standing by. My name is Tina, and I will be your conference operator today. At this time, I would like to welcome everyone to the Tempus AI Fourth Quarter 2025 Fiscal Results Conference Call. At this time, all lines are in a listen-only mode to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. We respectfully request that you limit questions to on ...

Core Insights - Tempus AI is adopting a dual-engine model focusing on a rapidly growing Genomics franchise and a scaling data business supported by an expanding AI toolkit [1][2] - The company achieved non-GAAP profitability in Q3 2025, indicating operational momentum as revenue increases [1][8] - The revenue mix is primarily from North America, driven by oncology testing, hereditary screening, and a developing minimal residual disease (MRD) offering [1][2] Genomics and Data Services - Tempus AI aggregates multimodal clinical and lab data, commercializing it through Genomics and Data services, including an Insights platform [2] - The Genomics portfolio aids in therapy selection and disease monitoring through various DNA and RNA-based tests, while the Insights platform monetizes de-identified datasets and analytics for life sciences partners [2][9] - In 2024, Genomics accounted for approximately 65% of revenue, with Data and services contributing 35%, highlighting the growing significance of data licensing [9] Operating Performance - The company reached a key milestone of non-GAAP profitability in Q3, supported by disciplined MRD expansion and cost management [3][8] - EPS history and estimates show a trend towards reduced losses into 2026, reflecting operational leverage from scaling and improved revenue mix [3] Regulatory and Payment Factors - Tempus AI is working on Advanced Diagnostic Laboratory Test (ADLT) migrations, which could enhance pricing and reimbursement opportunities [4][8] - Current average reimbursement rates are below peers, and successful execution of ADLT transitions and payer coverage expansion is crucial for revenue quality and margin improvement [4][8] Growth Drivers - Growth is expected to be driven by increased MRD volumes as the adoption of the xM test expands and new use cases are identified [11] - Recent performance included a 31.3% EPS surprise and a 2.4% sales surprise, providing a positive context for upcoming financial results [11] Competitive Landscape - Illumina and Guardant Health are key competitors in the genomic tools and clinical applications space, providing insights into oncology testing demand and reimbursement pathways relevant to Tempus AI [12]

As filed with the Securities and Exchange Commission on June 13, 2024 Registration No. 333-279558 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 2 to FORM S-1 REGISTRATION STATEMENT UNDER Table of Contents THE SECURITIES ACT OF 1933 Tempus AI, Inc. (Exact name of Registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 7370 47-4903308 (Primary Standard Industrial Classification Code Number) 600 West Chicago Avenue, ...